In patients with cancer, proinflammatory cytokines induce hepcidin overproduction, leading to iron sequestration within macrophages and suppression of ferroportin-mediated intestinal iron absorption, which substantially limits the efficacy of oral iron therapy [7], although the biological and clinical impact of hepcidin appears to differ across tumor types [8]. This evidence concerns the gene SLC40A1 and neoplasm.